- Home
- BG vs MRNA Comparison
BG vs MRNA Comparison
Compare BG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BG
- MRNA
- Stock Information
- Founded
- BG 1818
- MRNA 2010
- Country
- BG United States
- MRNA United States
- Employees
- BG N/A
- MRNA N/A
- Industry
- BG Packaged Foods
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BG Consumer Staples
- MRNA Health Care
- Exchange
- BG Nasdaq
- MRNA Nasdaq
- Market Cap
- BG 10.8B
- MRNA 10.6B
- IPO Year
- BG N/A
- MRNA 2018
- Fundamental
- Price
- BG $74.55
- MRNA $27.35
- Analyst Decision
- BG Buy
- MRNA Hold
- Analyst Count
- BG 5
- MRNA 19
- Target Price
- BG $81.60
- MRNA $48.13
- AVG Volume (30 Days)
- BG 1.9M
- MRNA 13.9M
- Earning Date
- BG 07-30-2025
- MRNA 07-31-2025
- Dividend Yield
- BG 3.76%
- MRNA N/A
- EPS Growth
- BG N/A
- MRNA N/A
- EPS
- BG 7.82
- MRNA N/A
- Revenue
- BG $51,334,000,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- BG $0.06
- MRNA N/A
- Revenue Next Year
- BG $3.22
- MRNA $9.87
- P/E Ratio
- BG $9.53
- MRNA N/A
- Revenue Growth
- BG N/A
- MRNA N/A
- 52 Week Low
- BG $67.40
- MRNA $23.15
- 52 Week High
- BG $114.92
- MRNA $158.82
- Technical
- Relative Strength Index (RSI)
- BG 38.32
- MRNA 50.18
- Support Level
- BG $73.67
- MRNA $25.82
- Resistance Level
- BG $80.47
- MRNA $28.57
- Average True Range (ATR)
- BG 1.55
- MRNA 1.61
- MACD
- BG -0.70
- MRNA 0.14
- Stochastic Oscillator
- BG 11.69
- MRNA 29.17
About BG Bunge Limited
Bunge Global SA formerly Bunge Ltd is an agribusiness and food company with operations along the farm-to-consumer food chain. The company segments include Agribusiness; Refined and Specialty Oils; Milling; Sugar and Bioenergy and Corporate and Other. It generates maximum revenue from the Agribusiness segment. The company is an oilseed processor and producer of vegetable oils and protein meals, based on processing capacity, a grain processor, the seller of packaged plant-based oils, producer and seller of wheat flour, bakery mixes and corn-based products in North and South America.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.